No difference in endothelial microvasculation measured by peripheral arterial tonometry in patients with Sjögren’s disease and matched controls
Sjögren’s disease (SjD) is a connective tissue autoimmune disorder characterized by inflammatory infiltration of the exocrine glands, leading to symptoms such as dryness, pain, and fatigue. Additionally, up to 50% of patients may experience extraglandular manifestations. SjD patients face a higher c...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1563796/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850094999673241600 |
|---|---|
| author | Franziska Maria Tapken Nadine Zehrfeld Malin Abelmann Malin Abelmann Malin Abelmann Anna Charlotte Müller-Vahl Sabrina Benz Tabea Seeliger Thomas Skripuletz Torsten Witte Kristina Sonnenschein Kristina Sonnenschein Johann Bauersachs Udo Bavendiek Thomas Thum Anselm A. Derda Anselm A. Derda Diana Ernst |
| author_facet | Franziska Maria Tapken Nadine Zehrfeld Malin Abelmann Malin Abelmann Malin Abelmann Anna Charlotte Müller-Vahl Sabrina Benz Tabea Seeliger Thomas Skripuletz Torsten Witte Kristina Sonnenschein Kristina Sonnenschein Johann Bauersachs Udo Bavendiek Thomas Thum Anselm A. Derda Anselm A. Derda Diana Ernst |
| author_sort | Franziska Maria Tapken |
| collection | DOAJ |
| description | Sjögren’s disease (SjD) is a connective tissue autoimmune disorder characterized by inflammatory infiltration of the exocrine glands, leading to symptoms such as dryness, pain, and fatigue. Additionally, up to 50% of patients may experience extraglandular manifestations. SjD patients face a higher cardiovascular risk, including severe events like myocardial infarction and strokes, partly due to an increased likelihood of subclinical atherosclerosis. Therefore, identifying SjD patients at an early stage is essential to reduce morbidity and mortality. In this study, SjD patients who met the current ACR/EULAR 2016 classification criteria were consecutively enrolled in our outpatient clinic. A control cohort was recruited through a multimedia call for participation. To assess changes in endothelial functions, a reactive hyperemia index (RHI) was calculated using peripheral arterial tonometry with the EndoPAT® measurement device. RHI values below 1.67 were considered pathological. The dataset consists of 49 SjD patients and 27 healthy controls. Both groups had similar ages and comparable cardiovascular risk factors. No differences in RHI were observed between the two cohorts. The only significant factor that was predictive for a low RHI was an increased body mass index (p = 0.036). These findings suggest that EndoPAT measurements may not be a suitable method for detecting changes in endothelial function specific to patients with SjD. |
| format | Article |
| id | doaj-art-482b14bb2ee641d89acfbafd823f1065 |
| institution | DOAJ |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-482b14bb2ee641d89acfbafd823f10652025-08-20T02:41:32ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-07-011210.3389/fmed.2025.15637961563796No difference in endothelial microvasculation measured by peripheral arterial tonometry in patients with Sjögren’s disease and matched controlsFranziska Maria Tapken0Nadine Zehrfeld1Malin Abelmann2Malin Abelmann3Malin Abelmann4Anna Charlotte Müller-Vahl5Sabrina Benz6Tabea Seeliger7Thomas Skripuletz8Torsten Witte9Kristina Sonnenschein10Kristina Sonnenschein11Johann Bauersachs12Udo Bavendiek13Thomas Thum14Anselm A. Derda15Anselm A. Derda16Diana Ernst17Department of Rheumatology and Immunology, Hannover Medical School, Hanover, GermanyDepartment of Rheumatology and Immunology, Hannover Medical School, Hanover, GermanyDepartment of Rheumatology and Immunology, Hannover Medical School, Hanover, GermanyDepartment of Angiology and Cardiology, Hannover Medical School, Hanover, GermanyInstitute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hanover, GermanyDepartment of Rheumatology and Immunology, Hannover Medical School, Hanover, GermanyDepartment of Psychology, Ludwig-Maximilians University Munich, Munich, GermanyDepartment of Neurology, Hannover Medical School, Hanover, GermanyDepartment of Neurology, Hannover Medical School, Hanover, GermanyDepartment of Rheumatology and Immunology, Hannover Medical School, Hanover, GermanyDepartment of Angiology and Cardiology, Hannover Medical School, Hanover, GermanyInstitute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hanover, GermanyDepartment of Angiology and Cardiology, Hannover Medical School, Hanover, GermanyDepartment of Angiology and Cardiology, Hannover Medical School, Hanover, GermanyInstitute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hanover, GermanyDepartment of Angiology and Cardiology, Hannover Medical School, Hanover, GermanyInstitute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hanover, GermanyDepartment of Rheumatology and Immunology, Hannover Medical School, Hanover, GermanySjögren’s disease (SjD) is a connective tissue autoimmune disorder characterized by inflammatory infiltration of the exocrine glands, leading to symptoms such as dryness, pain, and fatigue. Additionally, up to 50% of patients may experience extraglandular manifestations. SjD patients face a higher cardiovascular risk, including severe events like myocardial infarction and strokes, partly due to an increased likelihood of subclinical atherosclerosis. Therefore, identifying SjD patients at an early stage is essential to reduce morbidity and mortality. In this study, SjD patients who met the current ACR/EULAR 2016 classification criteria were consecutively enrolled in our outpatient clinic. A control cohort was recruited through a multimedia call for participation. To assess changes in endothelial functions, a reactive hyperemia index (RHI) was calculated using peripheral arterial tonometry with the EndoPAT® measurement device. RHI values below 1.67 were considered pathological. The dataset consists of 49 SjD patients and 27 healthy controls. Both groups had similar ages and comparable cardiovascular risk factors. No differences in RHI were observed between the two cohorts. The only significant factor that was predictive for a low RHI was an increased body mass index (p = 0.036). These findings suggest that EndoPAT measurements may not be a suitable method for detecting changes in endothelial function specific to patients with SjD.https://www.frontiersin.org/articles/10.3389/fmed.2025.1563796/fullendothelial dysfunctionSjögren’s diseasecardiovascular riskEndoPATperipheral arterial tonometrymiRNA |
| spellingShingle | Franziska Maria Tapken Nadine Zehrfeld Malin Abelmann Malin Abelmann Malin Abelmann Anna Charlotte Müller-Vahl Sabrina Benz Tabea Seeliger Thomas Skripuletz Torsten Witte Kristina Sonnenschein Kristina Sonnenschein Johann Bauersachs Udo Bavendiek Thomas Thum Anselm A. Derda Anselm A. Derda Diana Ernst No difference in endothelial microvasculation measured by peripheral arterial tonometry in patients with Sjögren’s disease and matched controls Frontiers in Medicine endothelial dysfunction Sjögren’s disease cardiovascular risk EndoPAT peripheral arterial tonometry miRNA |
| title | No difference in endothelial microvasculation measured by peripheral arterial tonometry in patients with Sjögren’s disease and matched controls |
| title_full | No difference in endothelial microvasculation measured by peripheral arterial tonometry in patients with Sjögren’s disease and matched controls |
| title_fullStr | No difference in endothelial microvasculation measured by peripheral arterial tonometry in patients with Sjögren’s disease and matched controls |
| title_full_unstemmed | No difference in endothelial microvasculation measured by peripheral arterial tonometry in patients with Sjögren’s disease and matched controls |
| title_short | No difference in endothelial microvasculation measured by peripheral arterial tonometry in patients with Sjögren’s disease and matched controls |
| title_sort | no difference in endothelial microvasculation measured by peripheral arterial tonometry in patients with sjogren s disease and matched controls |
| topic | endothelial dysfunction Sjögren’s disease cardiovascular risk EndoPAT peripheral arterial tonometry miRNA |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1563796/full |
| work_keys_str_mv | AT franziskamariatapken nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT nadinezehrfeld nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT malinabelmann nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT malinabelmann nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT malinabelmann nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT annacharlottemullervahl nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT sabrinabenz nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT tabeaseeliger nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT thomasskripuletz nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT torstenwitte nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT kristinasonnenschein nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT kristinasonnenschein nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT johannbauersachs nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT udobavendiek nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT thomasthum nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT anselmaderda nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT anselmaderda nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols AT dianaernst nodifferenceinendothelialmicrovasculationmeasuredbyperipheralarterialtonometryinpatientswithsjogrensdiseaseandmatchedcontrols |